Scribe Therapeutics Inc. (Nasdaq: SCTX) reported financial results for the third quarter ended September 30, 2026, and provided an update on its clinical pipeline and corporate milestones. The company, which focuses on in vivo CRISPR technologies for disease prevention, announced that its cash, cash equivalents, and marketable securities totaled $174.2 million as of September 30, 2026. This represents a significant increase from $43.0 million at the end of the prior quarter, driven primarily by approximately $140.2 million in net proceeds from the company's upsized initial public offering and concurrent private placement completed in July 2026.
Based on its current operating plan, Scribe Therapeutics stated that its cash position is sufficient to fund its operating expenses and capital expenditure requirements into the first half of 2029. For the three months ended September 30, 2026, the company reported a net loss of $9.9 million, or $0.68 per basic and diluted share. This compared to a net loss of $6.5 million for the same period in the prior year. Research and development expenses for the quarter were $8.3 million, while general and administrative expenses totaled $4.2 million.
In terms of clinical progress, Scribe Therapeutics highlighted its lead asset, STX-1150, an in vivo epigenetic silencing therapy for low-density lipoprotein cholesterol (LDL-C) lowering. The company stated that enrollment in the first-in-human Phase 1 clinical trial of STX-1150 is ongoing, with initial clinical data expected in the first half of 2027. The company also presented late-breaking data at the American Heart Association (AHA) Scientific Sessions 2026 meeting, demonstrating that a single administration of STX-1150 at a dose of 0.75 mg/kg resulted in durable LDL-C reductions of greater than 50% sustained for two years in non-human primates.
Another pipeline candidate, STX-1200, is an in vivo gene editing therapy designed to lower lipoprotein(a) (Lp(a)). Scribe reported that data for STX-1200 was presented at the AHA Scientific Sessions 2026 meeting, showing that preclinical surrogates achieved greater than 95% Lp(a) reduction in non-human primates. Additionally, the company announced an expansion of its strategic collaboration with Sanofi, which now provides access to Scribe's ELXR epigenetic silencing technology alongside its XE gene-editing technology.
